IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA
Adalgisa Condoluci(Ente Ospedaliero Cantonale), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Micol Giulia Cittone(Institute of Oncology Research), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Silke Gillessen(Institute of Oncology Research), Francesco Passamonti(University of Milan), Georg Stüssi(Institute of Oncology Research), Daniela Gussetti(Centro di Riferimento Oncologico), Maria Cristina Pirosa(Institute of Oncology Research), Marina Deodato(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Francesco Autore(Agostino Gemelli University Polyclinic), Pietro Bulian(Centro di Riferimento Oncologico), Luca Laurenti(Sapienza University of Rome), Lydia Scarfò(IRCCS Ospedale San Raffaele), Deborah Piffaretti(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Franco Cavalli(Institute of Social and Preventive Medicine), Katia Pini(Institute of Oncology Research), Annagiulia Zanatta(Centro di Riferimento Oncologico), B. Gerber(University of Zurich), Michele Merli(University of Insubria), Anna Maria Frustaci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Gabriela Forestieri(Institute of Oncology Research), Ricardo Koch(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Lodovico Terzi-di-Bergamo(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gaby Fahrni(University of Lucerne), Clara Deambrogi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Roberta Mattarucchi(University of Insubria), Martin Faderl(Institute of Oncology Research), Paolo Ghia(Vita-Salute San Raffaele University), Emanuele Zucca(Università della Svizzera italiana), Michael Gregor(University of Lucerne), Alessio Bruscaggin(Institute of Oncology Research), Valeria Spina(Ente Ospedaliero Cantonale), Jakob Passweg(University Hospital of Basel)
Cited by 0
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k